| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg | |||
| 250mg | |||
| Other Sizes |
| Targets |
DNA G-quadruplex (G4) - ligand that stabilizes and induces conformational changes in G4 structures.
|
|---|---|
| ln Vitro |
In vitro studies demonstrate that BMVC-8C3O is a novel ligand of DNA G-quadruplex (G4) that induces topological conversion of non-parallel to parallel forms in human telomeric DNA G4s. The compound increases the melting temperature of human telomeres by 45°C in a potassium solution, indicating strong stabilization of G-quadruplex structures. BMVC-8C3O also effectively suppresses c-FOS expression by stabilizing G-rich sequences located at the c-FOS promoter. The compound displays potential intracellular anti-tuberculosis activity in macrophages, suggesting that G-quadruplex targeting may have applications in infectious disease research. BMVC-8C3O is also effective against non-small cell lung cancer, highlighting its potential as an anticancer agent.
|
| ln Vivo |
In vivo studies on BMVC-8C3O are limited, as the compound is primarily used as a research tool for in vitro investigations of G-quadruplex biology and its role in gene regulation. The compound's ability to stabilize G-quadruplex structures and modulate gene expression suggests potential applications in cancer therapy, where G-quadruplex targeting is being explored as a strategy to inhibit telomerase activity and oncogene expression. The compound's potential intracellular anti-tuberculosis activity also warrants further investigation in animal models of tuberculosis. Further studies are needed to assess the compound's pharmacokinetic properties and efficacy in vivo.
|
| Enzyme Assay |
For G-quadruplex binding studies, biophysical assays such as fluorescence resonance energy transfer (FRET) melting assays, circular dichroism (CD) spectroscopy, and isothermal titration calorimetry (ITC) are performed using synthetic G-quadruplex-forming oligonucleotides (e.g., human telomeric sequence). The compound is incubated with the oligonucleotide, and changes in melting temperature, CD spectra, or binding thermodynamics are measured. The ability of BMVC-8C3O to induce topological conversion from non-parallel to parallel forms is assessed by CD spectroscopy, which distinguishes different G-quadruplex conformations. Binding affinity is calculated from the binding isotherms.
|
| Cell Assay |
Cellular assays for BMVC-8C3O typically involve culturing cancer cell lines (such as non-small cell lung cancer cells) or macrophages infected with Mycobacterium tuberculosis. Cells are treated with the compound at various concentrations, and cell viability is assessed using MTT or CCK-8 assays. c-FOS expression is measured by quantitative RT-PCR or Western blotting. For anti-tuberculosis activity, intracellular bacterial survival is assessed by colony counting after macrophage lysis. Telomere dysfunction is evaluated by measuring telomere length, telomerase activity, or by immunofluorescence staining of telomere-associated proteins. IC50 values for anti-proliferative effects are calculated from dose-response curves.
|
| Animal Protocol |
In vivo efficacy of BMVC-8C3O is evaluated in mouse models of non-small cell lung cancer or tuberculosis. For cancer studies, xenograft mouse models are used where tumor-bearing mice are treated with the compound via intravenous or intraperitoneal administration. Tumor volume is measured over time, and tumor tissues are analyzed for c-FOS expression and G-quadruplex stabilization. For tuberculosis studies, mice are infected with Mycobacterium tuberculosis and then treated with BMVC-8C3O. Bacterial load in the lungs and spleen is determined by colony counting, and histopathological examination of lung tissues is performed. Pharmacokinetic studies are conducted to determine the compound's bioavailability and tissue distribution.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of BMVC-8C3O have been characterized to support its use as a research tool. The compound's high molecular weight of 1042.61 and cationic nature (due to the three iodide counterions) influence its absorption, distribution, metabolism, and excretion (ADME) characteristics. Key PK parameters including half-life, clearance, volume of distribution, and bioavailability are determined using LC-MS/MS analysis of plasma and tissue samples following administration. The compound's ability to reach target tissues such as tumors and lungs is important for its efficacy in in vivo studies. The compound's polycationic nature may affect its tissue distribution and cellular uptake.
|
| Toxicity/Toxicokinetics |
Toxicological evaluation of BMVC-8C3O is typically conducted in parallel with efficacy studies in cell-based and animal models. Standard toxicology assessments include in vitro cytotoxicity assays against a panel of normal and cancer cell lines to determine the compound's selectivity index. In vivo toxicity studies in rodents include acute toxicity testing to determine the maximum tolerated dose, observation of clinical signs and body weight changes, and histopathological examination of major organs following repeated dosing. As a G-quadruplex ligand, potential effects on telomere maintenance, gene expression, and genomic stability are carefully monitored. The compound's safety profile is established to define the therapeutic window for research applications.
|
| Additional Infomation |
BMVC-8C3O is a research tool compound used for studying G-quadruplex biology and its role in gene regulation, telomere maintenance, and disease. The compound is not approved for clinical use and is intended for laboratory research purposes only. Its mechanism of action involves binding to and stabilizing G-quadruplex structures in DNA, including those in human telomeres and the c-FOS promoter. By stabilizing G-quadruplexes, the compound modulates gene expression, suppresses c-FOS expression, and induces antiproliferative effects in cancer cells. The compound also displays potential intracellular anti-tuberculosis activity. BMVC-8C3O is valuable for investigating the therapeutic potential of G-quadruplex targeting in cancer and infectious diseases.
|
| Molecular Formula |
C42H53I3N4O3
|
|---|---|
| Molecular Weight |
1042.6086
|
| Exact Mass |
1042.125
|
| Elemental Analysis |
C, 48.38 H, 5.12 I, 36.51 N, 5.37 O, 4.60
|
| CAS # |
1301708-12-2
|
| PubChem CID |
52934752
|
| Appearance |
Typically exists as solid at room temperature
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
16
|
| Heavy Atom Count |
52
|
| Complexity |
944
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C[N+]1=CC=C(C=C1)/C=C/C2=CC3=C(N(C4=C3C=C(C=C4)/C=C/C5=CC=[N+](C=C5)C)CCOCCOCCOCC[N+]6(CCCCC6)C)C=C2.[I-].[I-].[I-]
|
| InChi Key |
DKMJOQQQBQBOMV-UHFFFAOYSA-K
|
| InChi Code |
InChI=1S/C42H53N4O3.3HI/c1-43-19-15-35(16-20-43)7-9-37-11-13-41-39(33-37)40-34-38(10-8-36-17-21-44(2)22-18-36)12-14-42(40)45(41)23-27-47-29-31-49-32-30-48-28-26-46(3)24-5-4-6-25-46/h7-22,33-34H,4-6,23-32H2,1-3H33*1H/q+3/p-3
|
| Chemical Name |
9-[2-[2-[2-[2-(1-methylpiperidin-1-ium-1-yl)ethoxy]ethoxy]ethoxy]ethyl]-3,6-bis[(E)-2-(1-methylpyridin-1-ium-4-yl)ethenyl]carbazole;triiodide
|
| Synonyms |
BMVC-8C3O BMVC 8C3O BMVC8C3O
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.9591 mL | 4.7957 mL | 9.5913 mL | |
| 5 mM | 0.1918 mL | 0.9591 mL | 1.9183 mL | |
| 10 mM | 0.0959 mL | 0.4796 mL | 0.9591 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
